Format

Send to

Choose Destination
Cold Spring Harb Perspect Med. 2013 Mar 1;3(3):a012153. doi: 10.1101/cshperspect.a012153.

Translational research in nicotine dependence.

Author information

1
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

Nicotine addiction accounts for 4.9 million deaths each year. Furthermore, although smoking represents a significant health burden in the United States, at present there are only three FDA-approved pharmacotherapies currently on the market: (1) nicotine replacement therapy, (2) bupropion, and (3) varenicline. Despite this obvious gap in the market, the complexity of nicotine addiction in addition to the increasing cost of drug development makes targeted drug development prohibitive. Furthermore, using combinations of mouse and human studies, additional treatments could be developed from off-the-shelf, currently approved medication lists. This article reviews translational studies targeting manipulations of the cholinergic system as a viable therapeutic target for nicotine addiction.

PMID:
23335115
PMCID:
PMC3579204
DOI:
10.1101/cshperspect.a012153
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center